GCB-27a
GCB-27a is a CD1d-binding immunostimulant and antitumor agent. GCB-27a binds to CD1d to form a stable complex and presents it to NKT cells, enhancing hydrophobic interactions within the A' pocket of CD1d through branched-chain conformation restriction. GCB-27a induces a Th1-biased immune response, drives IFN?γ production and limits IL-4 levels. GCB-27a is applicable to research related to melanoma lung metastasis.
For research use only. We do not sell to patients.
- Formula: C52H95NO10
- Molecular Weight:894.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
GCB-27a (1-1000 nM; 72 h) potently stimulates Th1-biased cytokine production in C57BL/6 mouse splenocytes in vitro, with elevated IFN-γ secretion across all tested concentrations and no associated cytotoxicity[1].
GCB-27a (100 nM; 2-24 h) forms more stable and sustained complexes with mouse CD1d on BMDC surfaces than αGalCer, as measured by enhanced and prolonged L363 antibody binding[1].
GCB-27a (24 h) potently induces Th1-biased cytokine production in human NKT cells, with a 2-fold higher frequency of IFN-γ+ cells than αGalCer and comparable IL-4 induction[1].
GCB-27a has stronger binding affinity for both human and murine CD1d than αGalCer, due to optimized hydrophobic interactions and conformational preorganization within the CD1d A' pocket[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
GCB-27a (2.33 nmol per mouse; i.p.; single injection) potently activates innate immune cells in C57BL/6 mice, enhancing DC maturation marker expression and increasing the frequency of IFN-γ-secreting NK cells[1].
GCB-27a (0.58 nmol per mouse; i.p.; single injection) exhibits potent antitumor efficacy in a murine melanoma lung metastasis model, reducing metastatic nodule counts by 89% relative to αGalCer via a sustained Th1-biased immune response[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (n=5)[1]
-
Dosage:2.33 nmol per mouse
-
Administration:i.p.; single injection
-
Result:Induced a 10.9-fold increase in serum IFN-γ levels relative to αGalCer at 24 hours post-injection.
Maintained IL-4 levels comparable to those induced by αGalCer.
Demonstrated the strongest Th1 selectivity among all tested analogs, with the highest IFN-γ/IL-4 ratio fold change over αGalCer.
Confirmed sustained Th1-biased activity via time-dependent cytokine analysis, with peak IFN-γ levels observed at 24 hours post-injection.
-
Animal Model:C57BL/6 mice (n=3)[1]
-
Dosage:2.33 nmol per mouse
-
Administration:i.p.; single injection
-
Result:Markedly increased CD80 and CD86 expression on CD11c+ DCs relative to αGalCer.
Elevated the frequency of IFN-γ-producing NK cells to ~20% of splenic NK cells, a significant increase compared to αGalCer.
-
Animal Model:C57BL/6 mice (n=6; melanoma lung metastasis model)[1]
-
Dosage:0.58 nmol per mouse
-
Administration:i.p.; single injection
-
Result:Elicited significantly elevated serum IFN-γ levels relative to αGalCer, while IL-4 levels remained comparable to αGalCer.
Achieved an 89% decrease in lung metastatic nodule counts relative to the αGalCer-treated group.
Revealed near-complete inhibition of lung metastasis via histological analysis.
Chemical Information
-
Molecular Weight 894.31
-
Formula C52H95NO10
-
SMILES
O[C@H]1[C@@H](CO)O[C@H](OC[C@H](NC(CC2=CC=C(OCC(CCCCCCCC)CCCCCCCCCC)C=C2)=O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC)[C@H](O)[C@H]1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Tail-Vein Experimental Metastasis Xenograft
Tail-vein experimental metastasis xenograft models assess the ability of injected tumor cells to survive circulation, arrest in vascular beds, extravasate, and colonize distant organs, most commonly lung after lateral tail-vein injection; this model bypasses primary-tumor formation, local invasion, and intravasation, so the readout reflects late metastatic colonization rather than the full metastatic cascade. The main readouts are metastatic burden measured by bioluminescence imaging, gross metastatic nodules, histology, organ weight, survival, or ex vivo tumor-cell quantification; luciferase-labeled tumor cells permit longitudinal noninvasive monitoring, while histology confirms organ colonization and tissue localization.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)